Status
Conditions
Treatments
About
This study is intended to demonstrate that the Simplify® Cervical Artificial Disc (Simplify® Disc) is at least as safe and effective as conventional anterior cervical discectomy and fusion (ACDF) when used to treat two contiguous discs from C3 to C7 following discectomy at two contiguous levels for intractable radiculopathy (arm pain and/or a neurological deficit) with neck pain or myelopathy due to abnormalities localized to the levels of the two contiguous disc spaces in subjects who are unresponsive to conservative management.
Full description
The objective of this clinical study is to evaluate the safety and effectiveness of the two-level Simplify® Disc compared to conventional two-level ACDF in skeletally mature patients for reconstruction of two contiguous discs from C3 to C7 following discectomy at two contiguous levels for intractable radiculopathy (arm pain and/or a neurological deficit) with neck pain or myelopathy due to abnormalities localized to the levels of the two contiguous disc spaces that are unresponsive to conservative management.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Has a cervical spinal condition other than symptomatic cervical DDD requiring surgical treatment at the involved levels;
Has documented or diagnosed cervical instability relative to adjacent segments at either level, defined by dynamic (flexion/extension) radiographs showing:
Has more than two cervical levels requiring surgical treatment;
Has a fused level (or artificial disc replacement) adjacent to the levels to be treated;
Has severe pathology of the facet joints of the involved vertebral bodies;
Has had previous surgical intervention at either one or both of the involved levels or at adjacent levels;
Axial neck pain only (no radicular or myelopathy symptoms);
Has been previously diagnosed with osteopenia or osteomalacia;
Has any of the following that may be associated with a diagnosis of osteoporosis (if "Yes" to any of the below risk factors, a DEXA Scan will be required to determine eligibility):
Has presence of spinal metastases;
Has overt or active bacterial infection, either local or systemic;
Has insulin-dependent diabetes;
Has chronic or acute renal failure or prior history of renal disease;
Known PEEK, ceramic, titanium allergy;
Is mentally incompetent (if questionable, obtain psychiatric consult);
Is a prisoner;
Is pregnant;
Is currently an alcohol and/or drug abuser or currently undergoing treatment for alcohol and/or drug abuse;
Is involved with current or pending litigation regarding a spinal condition;
Has received drugs that may interfere with bone metabolism within two weeks prior to the planned date of spinal surgery (e.g., steroids or methotrexate), excluding routine perioperative anti-inflammatory drugs;
Has a history of an endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's Disease, renal osteodystrophy, Ehlers-Danlos Syndrome, or osteogenesis imperfecta);
Has a condition that requires postoperative medications that interfere with the stability of the implant, such as steroids. (This does not include low-dose aspirin for prophylactic anticoagulation and routine perioperative anti-inflammatory drugs);
Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following implantation.
Primary purpose
Allocation
Interventional model
Masking
182 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal